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Abstrak
Latar Belakang: Pengobatan kanker di Indonesia umumnya menggunakan pengobatan dengan 
kemoterapi atau dengan operasi.  Efek samping dari pengobatan ini antara lain adalah kerontokan 
rambut, mual dan penurunan berat badan.  Saat ini sedang berkembang alternatif terapi kanker 
dengan menggunakan immunoterapi.  Kemampuan sel kanker untuk menghindar dari sistem imun 
disebabkan adanya protein PD-1 pada sel T yang berikatan dengan ligannya PD-L1.  
Metode: Penelitian ini merupakan penelitian awal yaitu pembuatan rekombinan PQE PD-1 dan 
menggunakan bagian soluble dari PD-1 yang disebut dengan EP2PD1 yang akan digunakan untuk 
pembuatan antibodi monoklonal dan sistem pendeteksi antibodi monoklonal. Metode pembuatan 
rekombinan PD-1 dan EP2PD1 dengan cara penentuan sekuens epitop sel B yang paling imunogenik 
dilanjutkan dengan amplifikasi sekuen tersebut dengan PCR dan diligasi ke vektor pengekspresi PQE80. 
Hasil: Telah terbentuk konstruksi rekombinan PQE80 PD-1 dan PQEEP2PD1 yang diverifikasi 
menggunakan PCR koloni, pemotongan enzimatik dan sekuensing. Hasil penelitian menunjukkan 
bahwa epitop PD1 telah terklona ke PQE 80 dan tidak ditemukan mutasi dalam urutan asam amino.
Kesimpulan: Konstruksi yang dibuat tidak mempunya mutasi dan dapat dilanjutkan untuk pembuatan 
antibodi monoklonal. (Health Science Journal of Indonesia 2019;10(1):1-7)
Kata Kunci: PD1, Epitop, Kanker, Immunotherapy
Abstract
Background: Medications on cancer to date in Indonesia is mostly by surgical or chemotherapy, 
this type of medications is not always curing the patients. The side effect of the chemotherapy drugs 
sometimes more challenging such as hair loss, nausea and lost weight. One of the promising targets 
for cancer is using immune therapy. Cancer cells can avoid immune response by surprising immunity 
through activation of specific inhibitory signalling pathways, referred to as immune checkpoints. 
Immune check points like PD-1, PD-L1 are breakthrough therapies in oncology and this monoclonal 
antibody have been approved by the FDA for treatment. In this research we develop full PD-1 and   
part of PD1 sequence as an insert then we construct with plasmid PQE80L. This recombinant called 
PQE PD-1 and PQEEP2PD1. The aim of this study is to make recombinant which would be used to 
detect PD1 full clone monoclonal antibodies.
Methods: In this study, we designed our recombinants using Indonesian HLA and others using in 
silico models, this prototype will not only cover  Indonesian patients but also other country. 
Result: The result showed that the epitope sequence of PD1 has been clone to PQE 80 wt and 
verified using colony PCR, Enzyme Digestion  and Sanger Sequencing.  The Clone than will be 
expressed and injected to animal model to produce antibody. 
Conclusion: Construction of recombinant PQE PD-1 and PQE EP2PD1 are constructed without any 
mutation in the sequence, this recombinant can be used in the next study for protein expression of 
PQE PD-1 and PQE EP2PD1. (Health Science Journal of Indonesia 2019;10(1):1-7)
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Current treatment of cervical dysplasia is limited 
to excisional or ablative procedures that remove 
or destroy cervical tissue. These procedures have 
efficacy rates of approximately 90% but are associated 
with morbidity and expense. Additionally, surgical 
treatments remove only the dysplastic tissue, leaving 
normal-appearing HPV-infected tissue untreated.1
There are five main therapeutic modalities for cancer: 
surgery, radiation, chemotherapy, targeted therapy, 
and immunotherapy. With a few exceptions, the 
first four modalities are focused squarely on cancer 
itself. Immunotherapy represents conceptually a 
unique way of dealing with cancer which is to focus 
on eliminating cancer indirectly by harnessing the 
power of the host’s immune system.1  The presence 
of tumour – associated inflammatory cells in tumours 
raises an important question, which is one of the most 
important challenges in oncology. During the early 
stage of tumour development, cytotoxic immune cells 
such as NK cells, and CD8+ recognize and eliminate 
the more immunogenic cancer cells.2
In 2011 the immune check point inhibitor (ipilimumab) 
that used CTLA-4 antibodies was approved by the 
FDA for melanoma therapy. There are currently 2 types 
of immune FDA approved therapy as treatment cancer 
(1) inhibitors of either the programmed death receptor 
1 (PD-1) or its ligand (PD-L1), or (2) cytotoxic T 
cell lymphocyte-associated protein 4 (CTLA-4).3,4 A 
good example of the advanced checkpoint molecules 
that mediates tumour -induced immune suppression 
is programmed death-1 (PD-1).  Physiologically, 
the PD-1/PD-L1 pathway had emerged as a result 
of the need to control the degree of inflammation at 
locations expressing the antigen, in order to protect 
normal tissue from damage. There was a remarkable 
expression of the PD-1 protein on the surface of all 
activated T cells. When a T cell recognizes the antigen 
expressed by the MHC complex on the target cell, 
inflammatory cytokines are produced, initiating the 
inflammatory process.5,6 
These cytokines result in PD-L1 expression in the 
tissue, activating the PD-1 protein on the T cell 
leading to immune tolerance, a phenomenon where 
the immune system lose the control to mount an 
inflammatory response, even in the presence of 
actionable antigens.5
The evolution of immune checkpoint inhibitors as 
anticancer treatment options represents one of the 
most successful approaches in cancer drug discovery 
in the past few years. Someday might be possible to 
make cancer an easy disease to cure. 
In this study, we constructed recombinant PQE80 with 
PD1 full sequences and recombinant of part of epit-
opes from PD1. The purpose of obtaining a full PD1 
sequence construction was to obtain PD1 protein to 
be injected into mice and to obtain PD1 monoclo-
nal antibody after going through the stages of mak-
ing monoclonal antibodies. Whereas the making of 
part of PD1 epitope which we call PQEEP2PD1 is 
intended as a detection and selection of monoclo-
nal antibody of full PD1 sequence. We designed se-
quence of Full PD1 and EP2PD1 with unique epit-
ope for single B-cell. Because monoclonal antibod-
ies generated from a single B cell, it is important to 
get sequence epitope with high affinity. To get this 
we analyze our full sequence PD1 using in silico 
method.  We use www.IEDB .org epitope B linear 
prediction with Kolaskar and Tongaonkar antigenic-
ity method, with threshold number 1,007. From the 
result we find that locations 145-217 of protein have 
threshold above 1,007. We amplified this sequence 
and become  EP2PD1 sequence.  This study gives a 
preliminary data in DNA level that is important for 
the future research in expression of PD1 protein and 
production of PD 1-anti monoclonal antibodies as 
therapies of cancerous diseases.
MATERIAL AND METHODS
Analysis of PD-1 Gene
The PD1 gene was made by conducting alignment 
genes from the genebank. After the alignment, 
codon optimization was done so that the gene that 
is ordered is easy to express. Codon optimization 
was performed using in silico. The optimized genes 
were added with  BamHI and SacI.  The gene were 
synthesised by Macrogene.
Analysis in-Silico of PD-1 Protein
In silico analysis (www.IEDB.org) was carried out 
to determine epitopes of B cells that play a role in 
the immunology process.  The analysed PD-1 DNA 
sequence was applied to websites and its results some 
epitopes for targeting PD-1 anti monoclonal antibodies.
Construction of Recombinant PQE80 PD-1and 
PQE EP2PD-1
The Synthetic PD-1 DNA fragment was restricted 
using BamHI and SacI enzymes .The restricted PD-1 
DNA fragment was inserted to vector PQE 80 that had 
been restricted by the same enzymes. The EP2PD1 
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were amplified using PCR with synthetic PD-1 as 
a template. Locations of EP2PD1 was at 147-217 as 
mentions above and amplified using primers and 
TaqHifi enzyme from Invitrogen.  After amplified, the 
amplicon then purified using PCR purification from 
Qiagen and digested using BamHI and SacI enzymes. 
The ligation was performed by using T4 enzyme and 
T4 DNA ligase.   The ratio of vector and insert DNAs 
for ligation  is 1: 3. Transformation was  conducted 
by chemical induction method using heat shock. The 
transformant value was 7.664 x 103 cfu efficiency is 
1.15 x 105 cfu / µgIn the results of the negative control 
transformation, no growing colonies were found 
so that there was no bacterial contamination when 
making competent TOP 10 E. coli cells. Selection of 
transformants was performed by PCR colonies. PCR. 
Primers PQE F: CCCGAAAAGTGCCACCTG and 
PQE R: GTTCTGAGGTCATTACTGG were used 
for PCR. The PCR was performed by the following 
compositions: 950C for 2 minutes for early denaturation, 
For denaturation we at 950C for 10 seconds, annealing 
at 950C for 30 seconds extended time at 680C for 1 
minute and final extension at 680C for 2 minutes the 
PCR cycle is 35 cycle. The thermal cycler (BioRad) 
was performed by the following condition. The PCR 
results were visualized at 0.8% agarose gel.
Sequencing
DNA sequencing was conducted to determine the 
correctness of DNA sequences and in-frame between 
DNA insert and plasmid DNA backbone. Sequencing 
were using sanger method and for analysis sequencing 
was analysed with Bio Edit software. Based on the 
sequencing results, the DNA insert was successfully 
inserted in the frame on the PQE80 vector. The 
sequencing results were then aligned with the reference 
sequence and initial DNA PD1 gene to known any 
mutations that were caused by cloning process. 
Ethical Clearence
The study is laboratory experiment which does not 
involve any human and animal as an object.
RESULTS
B Cell Epitop Prediction
A study was performed to determined which epitope 
might elicit cellular or humoral immune response. 
B-cell epitopes can be defined as a surface accessible 
clusters of amino acids, which are recognized by 
secreted antibodies or B-cell receptors.  Figure 1, 
analysis of linear epitope prediction was using with 
Kolaskar and Tongaonkar antigencity method, with 
threshold number 1,007 at www.IEDB.org. Briefly 
we input the PD-1 sequence to find which position 
have the highest rank. The threshold of peptide 
prediction is 1,007, epitope give score above the 
threshold is the epitope were amplified. 
Figure 1. Result of linear epitop B cell Prediction using Kolaskar and Tongaonkar antigencity method
Table 1. The score of prediction PD-1 epitop to B cell 
No Start End Peptide Lenght Score
1 6 24 TQRLCATRTICATTTCRAA 19 0,998
2 52 62 FTPLKIQFTII 11 1,011
3 70 76 ARIFFQR 7 0,963
4 85 92 GTTCCTAT 8 0,961
5 143 160 FCTQAFFNLCFRCQANCT 18 1,026
6 193 217 LTRLATIFRKCCQFIGLIARAHTIP 25 1,022
7 232 237 KGCIIT 6 1,052
From the result we choose peptide position at 145- 217 for amplification of EP2PD1 insert. As a template we 
use PD-1 full length (Table 1). 
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Amplification of EP2PD1
Full-length PD-1 sequence it was used to amplify 
EP2PD1 insert. Primer used in this amplification 
was purchase from IDT with forward sequence : 
5’-ccggaagcttatgcagattccg-3’ and reverse sequence : 
5’-ggccaagcttgctcgggctcat-3’. 
         
                                      
Figure 2. Amplification of EP2PD1 using PCR Taq Hifi 
Invitrogen.
Next, the amplification of EP2PD1 using PCR with 
Taq Hifi Polymerase, the amplicon had a molecular 
base pair 220  bp (figure 2, lane 2) which is consistent 
with the design of epitope prediction .
Detection of Insert PD-1 By PCR Colony
Verification of recombinant was using PCR colony. 
This PCR performed as early step to identified cloned 
that have PD1 insert. The colony use for this analysis 
is the colony from replica plating at ligation and 
transformation procedure which is 12 colony (Figure 3).
Figure 3. Replica plate of PQE80 PD-1
The Primer were use are PQE-forward and PQE-
reverse. Those primer amplified  Multiple Cloning Site 
(MCS) of PQE 80 which about  ± 175 bp. To confirm 
the colony has insert of PD-1, length of amplified 
DNA from PCR colony is   ± 1056 bp (175 bp + 881 
bp). Electrophoresis visualisation showed that colony 
number 2,3,4,6,and 8 are predicted carrying PD-1 
insert,  showed with band at ± 1056 bp.
PCR colony also conducted to PQEEP2PD1 using 
primer  PQE-forward and PQE-reverse confirm, to 
confirm the colony has insert of EP2PD-1, length of 
amplified DNA from PCR colony is   ± 395 bp (175 
bp + 220 bp). Electrophoresis visualisation at Figure 
5 showed that colony number 1,2,3,4, are predicted 
carrying EP2PD-11 insert.
Figure 4. PCR Colony result, lane M: Gene ruler marker from Invitrogen, Lane 1: colony PQE PD-1 No:1, Lane 2: colony 
PQE PD-1 No:2, Lane 3,: colony PQE PD-1 No:3 Lane 4 : colony PQE PD-1 No:4, Lane 5 : colony PQE PD-1 No:5, Lane 
6: colony PQE PD-1 No:6, Lane 7: colony PQE PD-1 No:7, Lane 8: colony PQE PD-1 No:8, Lane 9: colony PQE PD-1 
No:9 Lane 10 : colony PQE PD-1 No:10, Lane 11 ; colony PQE PD-1 No:11, Lane 12 : colony PQE PD-1 No:1
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Figure 5. PCR Colony result, lane 1: Gene ruler marker 
from Invitrogen, Lane 2: colony PQE EP2PD1 No:1, 
Lane 3: colony PQE EP2PD1  No:2, Lane 4,: PQE 
EP2PD1 No:3 Lane 5 : PQE EP2PD1 No:4
Verification of the insert PD-1 and EP2 PD-1 by 
restriction enzymes
Colony that predicted have insert of PD-1, then 
inoculate to Luria Berthani medium with volume of 
culture 3 ml overnight. The next day culture were 
performed plasmid isolation using QIAprep Spin 
Miniprep Kit. The concentration of DNA plasmid 
was 111,6 ng/µL with total volume of 41 µL and 
the ratio of A260/280 value is 1,92. After plasmid 
isolation we performed verification of insert using 
enzyme digestion with BamHI and SacI. The purpose 
of this method is to excrete PD-1 insert. Colonies 
containing insert will showed 4068 bp and 818 bp 
band (Figure 6).
           
Figure 6.  Verification of insert PQE PD-1 colony number 2,3,4,6,and 8 using BamHI and SacI. lane 1: Gene ruler 
marker from Invitrogen, Lane 2: PQE80 Uncut colony, Lane 3: PQE PD-1 Uncut, Lane 4,:PcDNA E6  Lane 5 : PQE 80 
cut BamHI-SacI, Lane 6 : PQE PD-1 (2) cut BamHI-SacI , Lane 7: PQE PD-1 (3) cut BamHI-SacI, Lane 8: PQE PD-1 
(4) cut BamHI-SacI, Lane 9: PQE PD-1 (6) cut BamHI-SacI, Lane 10: PQE PD-1 (8) cut BamHI-SacI
From the digestion result  using agarose 0,8% tells 
that colony with DNA fragment expected (818 bp) 
are colony PQE PD-1(3) and PQE PD-1(8).  
The same protocol also conducted to colony of PQE 
EP2PD1, for this colony the insert were excrete using 
BamHI and HindIII. All the digest verification protocol 
was performed single digest only, BamHI then followed 
by HindIII using NEB buffer 3 and incubate at 370C for 
4 hours. After incubation period the plasmid was ran at 
agarose gel 0,8% for visualisation.
DNA Sequencing
DNA sequencing was conducted to determine 
nucleotide bases of inserted DNA. DNA sequencing 
was using Sanger method, and for analysis was 
using BioEdit.  To find out if there is any mutation 
analysis was compare to reference gene from gene 
bank for PQE PD-1 (8) and fpr PQE EP2PD1 (1) 
was compare with full length of PQE PD-1(8).  From 
data sequencing result (Figure 8) we can find out 
that there is no mutation of PQE EP2PD1 (1) in the 
recombinant, also with the PQE PD-1 (8).  
                                              
Figure 7.  Verification of insert PQE EP2 PD-1 colony 
number 1,2, using BamHI and HindIII lane 1: Gene ruler 
marker from Invitrogen, Lane 2: PQE80 Uncut, Lane 
3: PQE80 cut with BamHI and HindIII , Lane 4,: PQE 
EP1PD-1 (1) cut BamHI and HindIII,    Lane 5 : PQE 
EP1PD-1 (2) cut BamHI and HindIII 
From Visualisation of digested plasmid was using agarose 
0,8% we can find that expected band (220 bp) was inserted 
to PQE 80 vector (Figure 7). 
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Figure 8. Sequencing result of PQE EP2PD1 (1) using Sanger method, comparation of sequence was using PD-1 full gene. 
Figure 9. Sequencing result of PQE PD-1 (8) using Sanger method, comparation of sequence was using PD-1 full gene. 
From sequencing result in Figure 9, we found that 
there is no mutation at recombinant PQE PD-1 (8). 
It means that this two clone a can be a candidate for 
antibody monoclonal development.
            
   
DISCUSSION
In this study, we have proved to be successful in 
constructing PD-1 human sequence and EP2PD1 
sequence into prokaryote expression system PQE80. 
The purpose of his study is to make recombinant of 
PQE PD-1 which is going to be use for development 
of antibody monoclonal PD1.  According to Xu 
research.6 not all part of PD1 are easily to express 
specially domain region but other studies showed that 
the extracellular domain of PD-1 could be express. 
One study was carried out to express a human PD-
1-GST fusion protein and it was also found that the 
fusion protein was completely in inclusion bodies.6 
EP2PD1 is located at 145-217 amino acid which is an 
extra cellular domain according to software https://
protein-sol.manchester.ac.uk  (data not showed). 
Since this epitope is protrude it is possible to make 
this epitope as tools for detect efficiency of antibody 
monoclonal PD-1 or as DNA vaccine which combine 
with other immunogenic factor.
This sequence were optimized to B cell because B 
cells expressing high-affinity antibodies differentiate 
into antibody-secreting plasma cells and memory 
B cells that mediate humoral immunity against 
pathogens7 but in spite of advance in B- cell epitope 
mapping , it is important to note that antibodies raise 
against peptides often lack the ability to bind native 
proteins due to unstructured nature of the peptide.9 In 
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this study we check the antigenicity of peptide using 
Kolaskar and Tongaankar method with threshold 
value 1,007.  At the score value not all epitopes have 
the highest score only four of them the rest is below 
the threshold. For constructing EP2PD1 we choose 
epitope position from 145- 217 which have threshold 
value higher than 1,007. This might be the meaning 
that this epitope doesn’t have proper activity to 
interact with circulating tumour reactive CD8+, these 
finding suggest that there is other factor to be added 
to modulate activity of epitope EP2PD1 like IL 12.10
E. coli was select in this study as expression system 
because this system have many advantages, it has 
doubling time is about 20 min11, it means that a 
culture with a 1/100 dilution of starter culture may 
reach stationary phase in a few hour, this make E.coli 
a robust system to amplified DNA and highly density 
cultures are easily to achieved.12 In this study we use 
PQE 80 (Qiagen) as vector plasmid because this 
vector have properties of 6x His tag at the N-Terminal 
of the protein, make it the insert if ligated in framed 
easily to purified13 and also the PQE series from 
Qiagen was provide with termination codons it 
means that the 3’ end of the insert does not need to 
determined accurately. 
In conclusion, construction of recombinant PQE PD-1 
and PQE EP2PD1 are constructed without any mutation 
in the sequence.  It is means that this recombinant can 
be used in the next study for protein expression of PQE 
PD-1 and PQE EP2PD1, which will be proceed to 
development of monoclonal antibodies.
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